Overview of Dr. Ingham
Dr. Matthew Ingham is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from UMass Chan Medical School and has been in practice 7 years. He is one of 375 doctors at New York-Presbyterian Hospital and one of 118 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 20 publications and over 500 citings.
Office
161 Fort Washington Ave
New York, NY 10032Fax+1 212-305-6861
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2010 - 2013
University of Massachusetts Medical SchoolClass of 2010
Certifications & Licensure
NY State Medical License 2013 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade.Karan Luthria, Parin Shah, Blake Caldwell, Johannes C Melms, Sinan Abuzaid
Clinical Cancer Research. 2024-10-01 - Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.Brian A Van Tine, Matthew A Ingham, Steven Attia, Christian F Meyer, John D Baird
Journal of Clinical Oncology. 2024-07-10 - 11 citationsPhase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).Matthew Ingham, Jacob B Allred, Li Chen, Biswasjit Das, Bose Kochupurakkal
Journal of Clinical Oncology. 2023-09-01
Press Mentions
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in NovemberNovember 1st, 2022- Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
- Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid TumorsJune 2nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
